Scan the code to dive deeper
22
2 3
OF
References: 1. Data on file, Glaukos Corporation. 2. Williams AM et al. Semin Ophthalmol.
2025;40(3):188-195. 3. Nordstrom BL et al. Am J Ophthalmol. 2005;140(4):598-606.
©2026 Glaukos Corporation. All rights reserved.
Glaukos is a registered trademark of Glaukos Corporation. PM-US-2921
Glaukos offers an Interventional Glaucoma portfolio as an alternative option
to topical medication, which eases the burden on you and your patients.
3
Speak with your Glaukos representative to learn more.
65%
of patients managed on
topical drops lapsed out
of care at 12 months vs
25% of those managed
procedurally
1
2.6x
greater likelihood of
being lost to follow-up
in patients on topical
drops vs those managed
procedurally
1
62%
of patients that lapsed
from care did not return
for 3 years
1
2.17x
higher risk of blindness
in patients that lapsed
for 3+ years
2
1
